(175 days)
No
The description focuses on stereotaxy principles and geometric calculations based on user-identified points, with no mention of AI or ML techniques.
No.
The device is a guidance system for diagnostic and interventional procedures, not a device that directly treats a condition.
No
The device is described as providing guidance for minimally invasive or interventional procedures, computing the 3D location of a region of interest to assist in procedures like biopsies or hookwire placement, rather than providing or aiding in a diagnosis itself.
No
The device description explicitly states that Pristina Serena is a "hardware and software add-on" and lists specific hardware components included in the add-on, such as a Biopsy Positioner, dedicated breast compression paddles, and mechanical adaptors.
Based on the provided information, the Pristina Serena device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples such as blood, urine, or tissue that have been taken from the human body. They are used to detect diseases, conditions, or infections.
- Pristina Serena's Function: The description clearly states that Pristina Serena is a hardware and software add-on to a mammography platform. Its purpose is to provide guidance for minimally invasive or interventional procedures in the breast using X-ray images. It helps determine the 3D location of a region of interest to guide procedures like biopsies and localizations.
- No Sample Analysis: The device does not analyze any biological samples taken from the patient. It processes imaging data (X-ray images) to provide spatial information for procedural guidance.
Therefore, Pristina Serena falls under the category of a medical device used for imaging and procedural guidance, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Pristina Serena option provides the three-dimensional locations, using information obtained from stereotactic pairs of two-dimensional X-ray images. This information provides guidance for a variety of minimally invasive or interventional procedures in the breast such as: vacuum assisted biopsy, core biopsy, pre-surgical localization (e.g. hookwire), and fine needle aspirations (FNA).
Product codes
MUE
Device Description
Pristina Serena is a hardware and software add-on to the Senographe Pristina mammography platform (cleared in K162268).
Pristina Serena uses the Stereotaxy principle to determine the three-dimensional (3D) location (X, Y and Z coordinates) of a region of interest in the breast (such as a suspicious lesion).
The stereotaxy biopsy process uses a stereo pair of +/-15° angulated 2D low-dose X-ray images of the compressed breast. The user identifies the point of interest in each image of the stereo pair, Pristina Serena computes the three dimensions coordinates (X,Y,Z) of the user-specified location in the stereo pair.
Pristina Serena uses the target lesion 3D coordinates and information on the geometry of the biopsy device to compute the position of a biopsy device holder that will allow intervention in the breast at the targeted position (biopsy of sample tissue or placement of a hookwire for guidance of surgical interventions).
The Pristina Serena add-on includes the following items:
Hardware: a Biopsy Positioner (BP) the main hardware component of the Pristina Serena option. It can be mounted on the Senographe Pristina in lieu of the Imaging Bucky. The purpose of the BP is to allows breast positioning and mechanical guidance to the target lesion for Biopsy medical application; dedicated breast compression paddles for Biopsy application; mechanical adaptors: pieces of hardware to allow mounting of several kind of biopsy devices on the Biopsy positioner arm. Software: A new software version for the Senographe Pristina platform which includes software to manage the Pristina Serena option. Labeling for the Biopsy Medical application.
Pristina Serena option is compatible with previously installed Senographe Pristina systems. Pristina Serena does not require any hardware modification on the Senographe Pristina platform.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
X-ray
Anatomical Site
breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The safety and performance of the Pristina Serena option was demonstrated through engineering bench performance testing such as:
Biopsy accuracy testing: verification of the geometrical accuracy between the target lesion identified on the X-ray Stereo pair images and the actual position of the biopsy needle tip (or needle notch). Image quality and dose performance testing to confirm that performance in Biopsy mode with Pristina Serena is substantially equivalent to that of Senographe Pristina screening/diagnostic imaging system. In addition, the device has successfully completed required design control testing per GE Healthcare's quality management system. No unexpected test results were obtained. The Pristina Serena option was designed and will be manufactured under the Quality System Regulations of 21CFR 820 and ISO 13485. The following quality assurance measures were applied to the development of the system:
Risk Analysis Design Reviews Software Development Lifecycle Testing on unit level (Module verification) Integration testing (System verification) Performance testing (Verification) Safety testing (Verification) Simulated use testing (Validation) These tests were performed to provide the requisite data to substantiate performance, claims, and ultimately substantial equivalence. Testing demonstrated that Pristina Serena performs according to specifications and functions as intended.
Key Metrics
Not Found
Predicate Device(s)
Senographe Stereo (K040125)
Reference Device(s)
Senographe Pristina (K162268)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1715 Full-field digital mammography system.
(a)
Identification. A full-field digital mammography system is a device intended to produce planar digital x-ray images of the entire breast. This generic type of device may include digital mammography acquisition software, full-field digital image receptor, acquisition workstation, automatic exposure control, image processing and reconstruction programs, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). The special control for the device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Full-Field Digital Mammography System.”See § 892.1(e) for the availability of this guidance document.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 14, 2018
GE Healthcare Gregory Pessato Regulatory Affairs Program Manager 283 rue de la Miniere Buc, 78530 FRANCE
Re: K173576
Trade/Device Name: Pristina Serena Regulation Number: 21 CFR 892.1715 Regulation Name: Full-Field Digital Mammography System Regulatory Class: Class II Product Code: MUE Dated: April 11, 2018 Received: April 13, 2018
Dear Gregory Pessato:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRHs Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael D. O'Hara For
Robert A. Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name Pristina Serena
Indications for Use (Describe)
The Pristina Serena option provides the three-dimensional locations, using information obtained from stereotactic pairs of two-dimensional X-ray images. This information provides guidance for a variety of minimally invasive or interventional procedures in the breast such as: vacuum assisted biopsy, core biopsy, pre-surgical localization (e.g. hookwire), and fine needle aspirations (FNA).
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/1 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized, cursive font in the center. The circle is surrounded by a thin white border, and there are four small white teardrop shapes evenly spaced around the perimeter of the circle.
510(k) Summary
In accordance with 21 CFR 807.92 the following summary of information is provided:
| Date: | March 28, 2018 |
|---|---|
| Submitter: | GE Healthcare |
| GE Medical Systems SCS | |
| 283 RUE DE LA MINIERE | |
| 78530 BUC - FRANCE | |
| Primary Contact Person: | Gregory Pessato, |
| Regulatory Affairs Program Manager, | |
| GE Medical Systems SCS, | |
| 283 RUE DE LA MINIERE | |
| 78530 BUC - FRANCE | |
| Phone : + 33 1 30 70 93 16 | |
| Email : gregorypessato@ge.com | |
| Secondary Contact Person: | Diane Uriell |
| Sr. Director of Regulatory Affairs, XR and Women's Health, | |
| GE Healthcare, | |
| Atlanta, Georgia - USA | |
| Phone +1 262 290 8212 | |
| Email: Diane.Uriell@ge.com | |
| Device Trade Name: | Pristina Serena |
| Common/Usual Name: | Stereotaxy biopsy guidance application for a Full Field Digital |
| Mammography System | |
| Classification Names: | 21 CFR 892.1715, Full-field digital mammography system, Class II |
| Product Code: | MUE |
| Predicate Device(s): | Senographe Stereo (K040125) |
| Reference Predicate(s) | Senographe Pristina (K162268) |
| Device Description: | Pristina Serena is a hardware and software add-on to the Senographe |
| Pristina mammography platform (cleared in K162268). | |
| Pristina Serena uses the Stereotaxy principle to determine the three- | |
| dimensional (3D) location (X, Y and Z coordinates) of a region of | |
| interest in the breast (such as a suspicious lesion). |
The stereotaxy biopsy process uses a stereo pair of +/-15° angulated
2D low-dose X-ray images of the compressed breast. The user
identifies the point of interest in each image of the stereo pair,
Pristina Serena computes the three dimensions coordinates (X,Y,Z) of
the user-specified location in the stereo pair.
Pristina Serena uses the target lesion 3D coordinates and information
on the geometry of the biopsy device to compute the position of a
biopsy device holder that will allow intervention in the breast at the
targeted position (biopsy of sample tissue or placement of a hookwire
for guidance of surgical interventions).
The Pristina Serena add-on includes the following items:
Hardware: a Biopsy Positioner (BP) the main hardware
component of the Pristina Serena option. It can be
mounted on the Senographe Pristina in lieu of the
Imaging Bucky. The purpose of the BP is to allows
breast positioning and mechanical guidance to the
target lesion for Biopsy medical application; dedicated breast compression paddles for Biopsy
application; mechanical adaptors: pieces of hardware to allow
mounting of several kind of biopsy devices on the
Biopsy positioner arm. Software: A new software version for the Senographe Pristina
platform which includes software to manage the Pristina
Serena option. Labeling for the Biopsy Medical application. |
| | Pristina Serena option is compatible with previously installed
Senographe Pristina systems. Pristina Serena does not require any
hardware modification on the Senographe Pristina platform. |
| Intended Use: | Pristina Serena is an optional accessory of Senographe Pristina
intended to provide accurate location of lesions in the breast in three
dimensions. |
| Indications for Use | The Pristina Serena option provides the three-dimensional location of
target lesions, using information obtained from stereotactic pairs of
two-dimensional X-ray images. This information provides guidance for
a variety of minimally invasive or interventional procedures in the |
| | breast such as: vacuum assisted biopsy, core biopsy, pre-surgical
localization (e.g. hookwire), and fine needle aspirations (FNA). |
| Device Comparison: | Pristina Serena uses the same fundamental technology as Senographe
Stereo in terms of lesion targeting technique (2D stereotactic biopsy),
stereotactic angle, needle approach (vertical or lateral), field of view
and attainable breast volume. Like its predicate, Pristina Serena
supports various breast biopsy and intervention devices. The
targeting accuracy of Pristina Serena is equivalent to that of
Senographe Stereo.
The main differences between Pristina Serena and Senographe Stereo
include:
- Ability to target a lesion above the compression paddle in
vertical approach; - Ability to switch needle approach without patient
repositioning; - A tilted needle axis to accommodate future 3D biopsy
application.
Pristina Serena uses the image chain of the Senographe Pristina
mammography platform, therefore delivering images of quality
equivalent to that of standard screening/diagnostic images. |
| Performance Testing | The safety and performance of the Pristina Serena option was
demonstrated through engineering bench performance testing such
as:
Biopsy accuracy testing: verification of the geometrical
accuracy between the target lesion identified on the X-ray
Stereo pair images and the actual position of the biopsy
needle tip (or needle notch). Image quality and dose performance testing to confirm that
performance in Biopsy mode with Pristina Serena is
substantially equivalent to that of Senographe Pristina
screening/diagnostic imaging system. In addition, the device has successfully completed required design
control testing per GE Healthcare's quality management system. No
unexpected test results were obtained. The Pristina Serena option
was designed and will be manufactured under the Quality System
Regulations of 21CFR 820 and ISO 13485. The following quality
assurance measures were applied to the development of the system:
Risk Analysis Design Reviews |
| | Software Development Lifecycle Testing on unit level (Module verification) Integration testing (System verification) Performance testing (Verification) Safety testing (Verification) Simulated use testing (Validation) These tests were performed to provide the requisite data to substantiate performance, claims, and ultimately substantial equivalence. Testing demonstrated that Pristina Serena performs according to specifications and functions as intended. |
| Substantial Equivalence
Determination: | Pristina Serena has the same indications for use as its predicate Device. It uses the same fundamental technology as Senographe Stereo. Differences between Pristina Serena and Senographe Stereo do not raise new questions of safety and effectiveness. The impact of differences between the predicate and new device has been assessed using established methods. Testing including conformance to standards; successful verification/validation; and additional bench performance testing, establish that Pristina Serena is substantially equivalent to its predicate Senographe Stereo (K040125) for biopsy functions and reference predicate Senographe Pristina (K162268) for imaging performance. |
4
Image /page/4/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'g' and 'e' intertwined in a stylized script, enclosed within a blue circle. There are also three droplet-like shapes surrounding the circle, giving the impression of motion or energy.
5
Image /page/5/Picture/0 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized font in the center. There are three white swirls around the outside of the circle. The logo is simple and recognizable.
6
Image /page/6/Picture/0 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized, cursive font in the center. There are white swirls around the letters, and a white border around the blue circle. The logo is simple and recognizable, and it is associated with a well-known company.